|
Temsirolimus Clinical Trials
5 actively recruiting trials across 4 locations
Also known as: CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779 +1 more
Pipeline
Early 1: 2Phase 2: 2
Top Sponsors
- Nader Sanai1
- Miller Children's & Women's Hospital Long Beach1
- M.D. Anderson Cancer Center1
- Canadian Cancer Trials Group1
- American Society of Clinical Oncology1
Indications
- Cancer5
- Advanced Solid Tumors2
- Lymphoma, Non-Hodgkin2
- Multiple Myeloma2
- Recurrent Sarcoma1
Other1 trial
Birmingham, Alabama1 trial
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
University of Alabama at Birmingham Comprehensive Cancer Center
Phase 2
Phoenix, Arizona1 trial
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
St. Joseph's Hospital and Medical Center
Early 1
Long Beach, California1 trial
Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence
Miller Children's and Women's Hospital Long Beach
Early 1
Houston, Texas1 trial
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.